FY 2025 Budget Resolution - Pharmaceutical Related Provisions
2025 · 1st Quarter (Jan 1 - Mar 31)
TAKEDA PHARMACEUTICALS AMERICA INC
Filed by TAKEDA PHARMACEUTICALS AMERICA, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 22, 2025
- Income
- Not reported
- Expenses
- $490,000.00
- Registrant
- TAKEDA PHARMACEUTICALS AMERICA, INC.
- Filing UUID
- 347613ce-f21e-48c4-bd7f-0b0496e922e7
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Tax incentive issues as they relate to proposed global supply chain bills Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits Administration's Global Tax Proposal General issues around 2025 Reconciliation/Inbound Concerns
General intellectual property policy issues Issues related to proposed tariffs - all pharmaceutical related provisions
Discussions around Supply Chain implications
Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Proposals related to amending the protected classes in Medicare Medicare payment proposals Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Discussions on biosimilars related to IRA Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on treatment of small molecule drugs related to IRA H.R.1 492 , S. 832, EPIC Act of 2025 H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act
Clarifying or reforming the 340B program Value-based drug contracting Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Customs Border Protection changes impacting southern border plasma collections Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills H.R. 1476, S. 694, PLASMA Act H.R. 2528, Association Health Plans Act H.R. 2214, DRUG Act
Literal federal measure citations: H.R. 1476, S. 694, H.R. 2528, H.R. 2214
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.